|
1
|
Murta-Nascimento C, Schmitz-Dräger BJ,
Zeegers MP, Steineck G, Kogevinas M, Real FX and Malats N:
Epidemiology of urinary bladder cancer: From tumor development to
patient's death. World J Urol. 25:285–295. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tavora F and Epstein JI: Bladder cancer,
pathological classification and staging. BJU Int. 102B:1216–1220.
2008. View Article : Google Scholar
|
|
3
|
Hall MC, Chang SS, Dalbagni G, Pruthi RS,
Seigne JD, Skinner EC, Wolf JS Jr and Schellhammer PF: Guideline
for the management of nonmuscle invasive bladder cancer (stages Ta,
T1, and Tis): 2007 update. J Urol. 178:2314–2330. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Witjes JA, Compérat E, Cowan NC, De Santis
M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG and Sherif A:
European Association of Urology: EAU guidelines on muscle-invasive
and metastatic bladder cancer: Summary of the 2013 guidelines. Eur
Urol. 65:778–792. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
von der Maase H, Hansen SW, Roberts JT,
Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A,
Lippert CM, et al: Gemcitabine and cisplatin versus methotrexate,
vinblastine, doxorubicin, and cisplatin in advanced or metastatic
bladder cancer: Results of a large, randomized, multinational,
multi-center, phase III study. J Clin Oncol. 18:3068–3077.
2000.PubMed/NCBI
|
|
6
|
George L, Bladou F, Bardou VJ, Gravis G,
Tallet A, Alzieu C, Serment G and Salem N: Clinical outcome in
patients with locally advanced bladder carcinoma treated with
conservative multimodality therapy. Urology. 64:488–493. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartlett JB, Dredge K and Dalgleish AG:
The evolution of thalidomide and its IMiD derivatives as anticancer
agents. Nat Rev Cancer. 4:314–322. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kumar S and Rajkumar SV: Thalidomide and
dexamethasone: Therapy for multiple myeloma. Expert Rev Anticancer
Ther. 5:759–766. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hideshima T, Chauhan D, Shima Y, Raje N,
Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, et
al: Thalidomide and its analogs overcome drug resistance of human
multiple myeloma cells to conventional therapy. Blood.
96:2943–2950. 2000.PubMed/NCBI
|
|
10
|
Gras J: Pomalidomide for patients with
multiple myeloma. Drugs Today (Barc). 49:555–562. 2013. View Article : Google Scholar
|
|
11
|
Andhavarapu S and Roy V: Immunomodulatory
drugs in multiple myeloma. Expert Rev Hematol. 6:69–82. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chanan-Khan AA, Swaika A, Paulus A, Kumar
SK, Mikhael JR, Rajkumar SV, Dispenzieri A and Lacy MQ:
Pomalidomide: The new immunomodulatory agent for the treatment of
multiple myeloma. Blood Cancer J. 3:e1432013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pinter M, Wichlas M, Schmid K, Plank C,
Müller C, Wrba F and Peck-Radosavljevic M: Thalidomide in advanced
hepatocellular carcinoma as antiangiogenic treatment approach: A
phase I/II trial. Eur J Gastroenterol Hepatol. 20:1012–1019. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yau T, Chan P, Wong H, Ng KK, Chok SH,
Cheung TT, Lam V, Epstein RJ, Fan ST and Poon RT: Efficacy and
tolerability of low-dose thalidomide as first-line systemic
treatment of patients with advanced hepatocellular carcinoma.
Oncology. 72(Suppl 1): S67–S71. 2007. View Article : Google Scholar
|
|
15
|
Fadul CE, Kingman LS, Meyer LP, Cole BF,
Eskey CJ, Rhodes CH, Roberts DW, Newton HB and Pipas JM: A phase II
study of thalidomide and irinotecan for treatment of glioblastoma
multiforme. J Neurooncol. 90:229–235. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Puduvalli VK, Giglio P, Groves MD, Hess
KR, Gilbert MR, Mahankali S, Jackson EF, Levin VA, Conrad CA, Hsu
SH, et al: Phase II trial of irinotecan and thalidomide in adults
with recurrent glioblastoma multiforme. Neurooncol. 10:216–222.
2008.
|
|
17
|
Sun P, Zhang LM, Sun DJ and Dong LL:
Inhibitory effect of thalidomide on growth of human hepatoma cell
line SMMC-7721 cells. Zhonghua Zhong Liu Za Zhi. 31:582–586.
2009.(In Chinese). PubMed/NCBI
|
|
18
|
Lin YC, Shun CT, Wu MS and Chen CC: A
novel anticancer effect of thalidomide: Inhibition of intercellular
adhesion molecule-1-mediated cell invasion and metastasis through
suppression of nuclear factor-kappaB. Clin Cancer Res.
12:7165–7173. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tzeng CC, Liu HS, Li C, Jin YT, Chen RM,
Yang WH and Lin JS: Characterization of two urothelium cancer cell
lines derived from a blackfoot disease endemic area in Taiwan.
Anticancer Res. 16A:1797–1804. 1996.
|
|
20
|
Huang YT, Lai PC, Wu CC, Hsu SH, Cheng CC,
Lan YF and Chiu TH: BDNF mediated TrkB activation is a survival
signal for transitional cell carcinoma cells. Int J Oncol.
36:1469–1476. 2010.PubMed/NCBI
|
|
21
|
Lai PC, Yang YC, Cheng CC, Chiu TH and
Huang YT: Brain-derived neurotrophic factor plus vascular
endothelial growth factor additively promotes early growth of the
transitional cell carcinoma cell line BFTC905 in vitro and in vivo.
Tzu Chi Med J. 25:155–160. 2013. View Article : Google Scholar
|
|
22
|
Huang YT, Cheng CC, Lin TC, Chiu TH and
Lai PC: Therapeutic potential of sepantronium bromide YM155 in
gemcitabine-resistant human urothelial carcinoma cells. Oncol Rep.
31:771–780. 2014.
|
|
23
|
Huang YT, Lai PC, Wu CC, Cheng CC and Chiu
TH: TrkB antibody elicits cytotoxicity and suppresses
migration/invasion of transitional cell carcinoma cells. Int J
Oncol. 37:943–949. 2010.PubMed/NCBI
|
|
24
|
Strober W: Trypan blue exclusion test of
cell viability. Curr Protoc Immunol. 3(Appendix): 3B2001.
|
|
25
|
Lai PC, Fang TC, Cheng CC, Chiu TH and
Huang YT: Lestaurtinib is cytotoxic to oxaliplatin-resistant
transitional cell carcinoma cell line T24 in vitro. Tzu Chi Med J.
22:125–130. 2010. View Article : Google Scholar
|
|
26
|
Erel O: A new automated colorimetric
method for measuring total oxidant status. Clin Biochem.
38:1103–1111. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hsu CW, Chen CY, Wang CS and Chiu TH:
Caffeine and a selective adenosine A2A receptor antagonist induce
reward and sensitization behavior associated with increased
phospho-Thr75-DARPP-32 in mice. Psychopharmacology (Berl).
204:313–325. 2009. View Article : Google Scholar
|
|
28
|
Buchser WJ, Laskow TC, Pavlik PJ, Lin HM
and Lotze MT: Cell-mediated autophagy promotes cancer cell
survival. Cancer Res. 72:2970–2979. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zheng G, Zhou M, Ou X, Peng B, Yu Y, Kong
F, Ouyang Y and He Z: Identification of carbonic anhydrase 9 as a
contributor to pingyangmycin-induced drug resistance in human
tongue cancer cells. FEBS J. 277:4506–4518. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu W, Shu X, Hovsepyan H, Mosteller RD and
Broek D: VEGF receptor expression and signaling in human bladder
tumors. Oncogene. 22:3361–3370. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Allen LE and Maher PA: Expression of basic
fibroblast growth factor and its receptor in an invasive bladder
carcinoma cell line. J Cell Physiol. 155:368–375. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li X, Liu X, Wang J, Wang Z, Jiang W, Reed
E, Zhang Y, Liu Y and Li QQ: Thalidomide down-regulates the
expression of VEGF and bFGF in cisplatin-resistant human lung
carcinoma cells. Anticancer Res. 23B:2481–2487. 2003.
|
|
33
|
Lee EJ, Kim WJ and Moon SK: Cordycepin
suppresses TNF-alpha-induced invasion, migration and matrix
metalloproteinase-9 expression in human bladder cancer cells.
Phytother Res. 24:1755–1761. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Moreira AL, Sampaio EP, Zmuidzinas A,
Frindt P, Smith KA and Kaplan G: Thalidomide exerts its inhibitory
action on tumor necrosis factor alpha by enhancing mRNA
degradation. J Exp Med. 177:1675–1680. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sherr CJ: Cancer cell cycles. Science.
274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hunter T and Pines J: Cyclins and cancer.
II: Cyclin D and CDK inhibitors come of age. Cell. 79:573–582.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Scholzen T and Gerdes J: The Ki-67
protein: From the known and the unknown. J Cell Physiol.
182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gerdes J, Li L, Schlueter C, Duchrow M,
Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E and Flad HD:
Immunobiochemical and molecular biologic characterization of the
cell proliferation-associated nuclear antigen that is defined by
monoclonal antibody Ki-67. Am J Pathol. 138:867–873.
1991.PubMed/NCBI
|
|
39
|
Ito T, Ando H, Suzuki T, Ogura T, Hotta K,
Imamura Y, Yamaguchi Y and Handa H: Identification of a primary
target of thalidomide teratogenicity. Science. 327:1345–1350. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Parman T, Wiley MJ and Wells PG: Free
radical-mediated oxidative DNA damage in the mechanism of
thalidomide teratogenicity. Nat Med. 5:582–585. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Donmez G, Sullu Y, Baris S, Yildiz L,
Aydin O, Karagoz F and Kandemir B: Vascular endothelial growth
factor (VEGF), matrix metalloproteinase-9 (MMP-9), and
thrombospondin-1 (TSP-1) expression in urothelial carcinomas.
Pathol Res Pract. 205:854–857. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ozer G, Altinel M, Kocak B, Balci M, Altan
A and Gonenc F: Potential value of soluble intercellular adhesion
molecule-1 in the serum of patients with bladder cancer. Urol Int.
70:167–171. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Oliver FJ, de la Rubia G, Rolli V,
Ruiz-Ruiz MC, de Murcia G and Murcia JM: Importance of
poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson
from an uncleavable mutant. J Biol Chem. 273:33533–33539. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bochner BH, Cote RJ, Weidner N, Groshen S,
Chen SC, Skinner DG and Nichols PW: Angiogenesis in bladder cancer:
Relationship between microvessel density and tumor prognosis. J
Natl Cancer Inst. 87:1603–1612. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nicolini A, Ferrari P, Masoni MC, Fini M,
Pagani S, Giampietro O and Carpi A: Malnutrition, anorexia and
cachexia in cancer patients: A mini-review on pathogenesis and
treatment. Biomed Pharmacother. 67:807–817. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Höglund P, Eriksson T and Björkman S: A
double-blind study of the sedative effects of the thalidomide
enantiomers in humans. J Pharmacokinet Biopharm. 26:363–383. 1998.
View Article : Google Scholar
|
|
47
|
Ridoux O and Drancourt M: Lack of in vitro
antimicrosporidian activity of thalidomide. Antimicrob Agents
Chemother. 43:2305–2306. 1999.PubMed/NCBI
|
|
48
|
Moreira AL, Wang J, Sarno EN and Kaplan G:
Thalidomide protects mice against LPS-induced shock. Braz J Med
Biol Res. 30:1199–1207. 1997. View Article : Google Scholar
|
|
49
|
Shannon EJ, Sandoval FG and Morales MJ: In
vitro thalidomide does not interfere with the activation of
complement by M. leprae. J Drugs Dermatol. 10:274–278.
2011.PubMed/NCBI
|
|
50
|
Mall JW, Schwenk W, Philipp AW, Müller JM
and Pollmann C: Thalidomide given intraperitoneally reduces the
number of postoperative adhesions after large bowel resection in
rabbits. Eur J Surg. 168:641–645. 2002. View Article : Google Scholar
|
|
51
|
D'Amato RJ, Loughnan MS, Flynn E and
Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl
Acad Sci USA. 91:4082–4085. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lentzsch S, LeBlanc R, Podar K, Davies F,
Lin B, Hideshima T, Catley L, Stirling DI and Anderson KC:
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan
cells and angiogenesis in vivo. Leukemia. 17:41–44. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Oz ES, Aydemir E and Fışkın K: DMSO
exhibits similar cytotoxicity effects to thalidomide in mouse
breast cancer cells. Oncol Lett. 3:927–929. 2012.PubMed/NCBI
|
|
54
|
Eter N and Spitznas M: DMSO mimics
inhibitory effect of thalidomide on choriocapillary endothelial
cell proliferation in culture. Br J Ophthalmol. 86:1303–1305. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Loftsson T and Duchêne D: Cyclodextrins
and their pharmaceutical applications. Int J Pharm. 329:1–11. 2007.
View Article : Google Scholar
|
|
56
|
Kratz JM, Teixeira MR, Ferronato K,
Teixeira HF, Koester LS and Simões CM: Preparation,
characterization, and in vitro intestinal permeability evaluation
of thalidomide-hydroxypropyl-β-cyclodextrin complexes. AAPS
PharmSciTech. 13:118–124. 2012. View Article : Google Scholar
|
|
57
|
Alvarez C, Calero J, Menéndez JC, Torrado
S and Torrado JJ: Effects of hydroxypropyl-beta-cyclodextrin on the
chemical stability and the aqueous solubility of thalidomide
enantiomers. Pharmazie. 63:511–513. 2008.PubMed/NCBI
|
|
58
|
Kale R, Tayade P, Saraf M and Juvekar A:
Molecular encapsulation of thalidomide with sulfobutyl ether-7
beta-cyclodextrin for immediate release property: Enhanced in vivo
antitumor and antiangiogenesis efficacy in mice. Drug Dev Ind
Pharm. 34:149–156. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Stella VJ, Rao VM, Zannou EA and Zia V:
Mechanisms of drug release from cyclodextrin complexes. Adv Drug
Deliv Rev. 36:3–16. 1999. View Article : Google Scholar
|
|
60
|
Kirsh EJ, Baunoch DA and Stadler WM:
Expression of bcl-2 and bcl-X in bladder cancer. J Urol.
159:1348–1353. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Sedlakova O, Svastova E, Takacova M,
Kopacek J, Pastorek J and Pastorekova S: Carbonic anhydrase IX, a
hypoxia-induced catalytic component of the pH regulating machinery
in tumors. Front Physiol. 4:4002014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Chen MC, Lee CF, Huang WH and Chou TC:
Magnolol suppresses hypoxia-induced angiogenesis via inhibition of
HIF-1α/VEGF signaling pathway in human bladder cancer cells.
Biochem Pharmacol. 85:1278–1287. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Borst P: Cancer drug pan-resistance:
Pumps, cancer stem cells, quiescence, epithelial to mesenchymal
transition, blocked cell death pathways, persisters or what? Open
Biol. 2:1200662012. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Goss PE and Chambers AF: Does tumour
dormancy offer a therapeutic target? Nat Rev Cancer. 10:871–877.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Podhorecka M, Halicka HD, Klimek P, Kowal
M and Dmoszynska A: Thalidomide induces phosphorylation of histone
H2AX and increases rate of apoptosis caused by fludarabine in
malignant lymphocytes of chronic lymphocytic leukemia in short-term
cell cultures. Leuk Res. 33:997–1000. 2009. View Article : Google Scholar
|
|
66
|
Yu J, Liu F, Sun Z, Sun M and Sun S: The
enhancement of radio-sensitivity in human esophageal carcinoma
cells by thalidomide and its potential mechanism. Cancer Biother
Radiopharm. 26:219–227. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Margulis V, Lotan Y and Shariat SF:
Survivin: A promising biomarker for detection and prognosis of
bladder cancer. World J Urol. 26:59–65. 2008. View Article : Google Scholar
|
|
68
|
Lai PC, Fang TC, Chiu TH and Huang YT:
Overexpression of securin in human transitional cell carcinoma
specimens. Tzu Chi Med J. 22:171–176. 2010. View Article : Google Scholar
|
|
69
|
Jian W, Levitt JM, Lerner SP and Sonpavde
G: The preclinical activity of lenalidomide in indolent urothelial
carcinoma. Anticancer Res. 34:3383–3389. 2014.PubMed/NCBI
|
|
70
|
Ren S, Xu C, Cui Z, Yu Y, Xu W, Wang F, Lu
J, Wei M, Lu X, Gao X, et al: Oncogenic CUL4A determines the
response to thalidomide treatment in prostate cancer. J Mol Med
Berl. 90:1121–1132. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Lopez-Girona A, Mendy D, Ito T, Miller K,
Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, et
al: Cereblon is a direct protein target for immunomodulatory and
antiproliferative activities of lenalidomide and pomalidomide.
Leukemia. 26:2326–2335. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Greenberg AJ, Walters DK, Kumar SK,
Vincent Rajkumar S and Jelinek DF: Responsiveness of
cytogenetically discrete human myeloma cell lines to lenalidomide:
Lack of correlation with cereblon and interferon regulatory factor
4 expression levels. Eur J Haematol. 91:504–513. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Puskás LG, Fehér LZ, Vizler C, Ayaydin F,
Rásó E, Molnár E, Magyary I, Kanizsai I, Gyuris M, Madácsi R, et
al: Polyunsaturated fatty acids synergize with lipid droplet
binding thalidomide analogs to induce oxidative stress in cancer
cells. Lipids Health Dis. 9:562010. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Lv P, Luo HS, Zhou XP, Xiao YJ, Paul SC,
Si XM and Zhou YH: Reversal effect of thalidomide on established
hepatic cirrhosis in rats via inhibition of nuclear
factor-kappaB/inhibitor of nuclear factor-kappaB pathway. Arch Med
Res. 38:15–27. 2007. View Article : Google Scholar
|
|
75
|
Piura B, Medina L, Rabinovich A, Dyomin V
and Huleihel M: Thalidomide distinctly affected TNF-α, IL-6 and MMP
secretion by an ovarian cancer cell line (SKOV-3) and primary
ovarian cancer cells. Eur Cytokine Netw. 24:122–129.
2013.PubMed/NCBI
|
|
76
|
Zhang S, Li M, Gu Y, Liu Z, Xu S, Cui Y
and Sun B: Thalidomide influences growth and vasculogenic mimicry
channel formation in melanoma. J Exp Clin Cancer Res. 27:602008.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Kotoh T, Dhar DK, Masunaga R, Tabara H,
Tachibana M, Kubota H, Kohno H and Nagasue N: Antiangiogenic
therapy of human esophageal cancers with thalidomide in nude mice.
Surgery. 125:536–544. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Sasano H and Suzuki T: Pathological
evaluation of angiogenesis in human tumor. Biomed Pharmacother.
59(Suppl 2): S334–S336. 2005. View Article : Google Scholar
|
|
79
|
Gordon JN, Trebble TM, Ellis RD, Duncan
HD, Johns T and Goggin PM: Thalidomide in the treatment of cancer
cachexia: A randomised placebo controlled trial. Gut. 54:540–545.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Grover JK, Uppal G and Raina V: The
adverse effects of thalidomide in relapsed and refractory patients
of multiple myeloma. Ann Oncol. 13:1636–1640. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Zhu D, Corral LG, Fleming YW and Stein B:
Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce
apoptosis of both hematological and solid tumor cells through NK
cell activation. Cancer Immunol Immunother. 57:1849–1859. 2008.
View Article : Google Scholar : PubMed/NCBI
|
